# Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome

> **NCT00666224** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 481 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Glatiramer Acetate (DB)
- **DRUG:** Placebo
- **DRUG:** Glatiramer Acetate (OL)

## Key facts

- **NCT ID:** NCT00666224
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2007-10
- **Final completion:** 2010-06
- **Target enrollment:** 481 (ACTUAL)
- **Last updated:** 2012-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00666224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00666224, "Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00666224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*